Drugs / stromal vascular fraction (SVF)
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02135380 | Aug 2014 → Aug 2015 | idiopathic pulmonary fibrosis | Kasiak Research Pvt. Ltd. | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07255547 | May 2019 → May 2026 overdue | arthropathy | University of L'Aquila | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02697682 | Mar 2016 → Jun 2017 | osteoarthritis | Hvidovre University Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | stromal vascular fraction (SVF) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07255547 ↗ |
| Known as | ADSVF | “Adipose Derived Stromal Vascular Fraction (ADSVF) Stromal Vascular Fraction (SVF) obtained from tumescent liposuction.” NCT02135380 ↗ |
| Modality | Cell therapy | “The SVF contains a variety of cells such as pre-adipocytes, endothelial cells, smooth muscle cells, pericytes, fibroblasts, and adult stem cells (ASCs).” NCT02135380 ↗ |
| Route | Intravenous | “Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.” NCT02135380 ↗ |